Stories about sodium valproate
Norman Lamb, chair of the Science and Technology Committee, led the debate. He said that there had been “systematic failure” to warn women of the risks of valproate since the 1970s.
The EMA assesses and oversees the safety of medicines in the EU. The announced public hearing is part of the EMA’s review into the use of valproate-based medicines in women who are pregnant or of childbearing age.